Welcome to our dedicated page for Eiger BioPharmaceuticals news (Ticker: EIGR), a resource for investors and traders seeking the latest updates and insights on Eiger BioPharmaceuticals stock.
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) is a commercial-stage biopharmaceutical company headquartered at 500 Crescent Ct Ste 300, Dallas, Texas. The company focuses on the development of innovative therapies for rare and ultra-rare diseases.
Recently, Eiger has redirected its efforts towards the development of avexitide for hyperinsulinemic hypoglycemia indications. This includes significant potential in treating post-bariatric hypoglycemia (PBH), where Phase 2 clinical trials have shown promising results, and the FDA has provided alignment on Phase 3 endpoints and study design. Eiger also plans to develop avexitide for congenital hyperinsulinism as a secondary indication.
The company continues to commercialize Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL). Eiger recently received marketing approval for Zokinvy in Japan through a partnership with AnGes, Inc., further expanding its global reach.
In a strategic move, Eiger is exploring partnering opportunities for its virology assets, including lonafarnib-based regimens for hepatitis delta virus (HDV) and peginterferon lambda. Despite recent challenges, such as the discontinuation of the Phase 3 LIMT-2 study of peginterferon lambda due to safety concerns, Eiger remains committed to its primary goals.
Financially, Eiger reported total revenue of $4.6 million for Q2 2023 and $3.2 million for Q3 2023, indicating a stable financial condition supported by strategic cost reductions and workforce optimization. The company’s cash runway is extended into the fourth quarter of 2024, enhancing its capacity to pursue ongoing projects and strategic initiatives.
As of January 2024, Eiger announced a 1-for-30 reverse stock split to comply with Nasdaq's listing requirements and maintain its market position. The company is also navigating a Chapter 11 bankruptcy process to facilitate an orderly wind down of its operations and the sale of its assets, including a “stalking horse” agreement for Zokinvy.
Dr. David Apelian, with extensive experience in clinical development and regulatory affairs, leads Eiger as its CEO, guiding the company through these transformative times.
For further details and updates, visit the company’s website at www.eigerbio.com.
Eiger BioPharmaceuticals (Nasdaq: EIGR) will host a conference call on May 5, 2022, at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update. The company specializes in developing therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes two first-in-class therapies currently in Phase 3 trials, with all five rare disease programs having received FDA breakthrough therapy designation. The webcast will be available for replay for at least 90 days.
Eiger BioPharmaceuticals appoints Chris Kurtz as Chief Technical Officer and Sarah Mathieson as Senior Vice President, Corporate Affairs. These appointments come as the company advances its late-stage pipeline, particularly for Hepatitis Delta Virus therapies. Eiger anticipates topline data from its Phase 3 D-LIVR study by the end of 2022, along with positive data from the TOGETHER study for COVID-19.
Kurtz brings 30 years of experience in technical operations, while Mathieson has 25 years in corporate communications.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced significant results from the Phase 3 TOGETHER study using Peginterferon Lambda. The trial, featuring 1,936 COVID-19 outpatient participants, showed Lambda reduced the risk of hospitalizations or ER visits by 50% and COVID-19-related deaths by 60%. The treatment demonstrated a 99.91% probability of superiority against placebo across multiple variants, including omicron. Eiger plans to submit data for Emergency Use Authorization (EUA) to the FDA.
Eiger BioPharmaceuticals (Nasdaq:EIGR) will host a conference call on March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern to discuss results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19. The company focuses on innovative therapies for Hepatitis Delta Virus (HDV) and other serious diseases, with multiple programs granted FDA Breakthrough Therapy Designation. Investors can access the live call or replay via the company's website.
Eiger BioPharmaceuticals (Nasdaq:EIGR) reported its fourth quarter and full year 2021 financial results. The company holds a strong cash position of approximately $106 million as of December 31, 2021. Key developments include the Phase 3 TOGETHER study for COVID-19 and the D-LIVR study for Hepatitis Delta Virus, with topline data expected in March and by the end of 2022, respectively. Revenue from Zokinvy was $3.4 million in Q4, with full-year sales at $12.1 million. Net losses were $21.8 million in Q4, compared to $18.8 million in the same period in 2020.
Eiger BioPharmaceuticals (Nasdaq:EIGR) is set to host a conference call on March 10, 2022, at 4:30 PM ET to discuss its fourth quarter and full year 2021 financial results. The call aims to provide a comprehensive business update for investors. Eiger is focused on developing innovative therapies targeting Hepatitis Delta Virus (HDV) and other rare diseases. Notably, all five of its rare disease programs have received FDA Breakthrough Therapy Designation, signifying strong progress in its clinical pipeline.
Eiger BioPharmaceuticals (Nasdaq:EIGR) provided a comprehensive outlook for 2022, focusing on its pipeline programs. Key highlights include the anticipated topline data from the pivotal D-LIVR Phase 3 study for Lonafarnib, expected by year-end. This trial represents the largest conducted in Hepatitis Delta Virus (HDV). Additionally, the company is enrolling patients in the LIMT-2 trial for Peginterferon Lambda. Eiger reported approximately $106 million in cash and equivalents at the start of 2022, emphasizing its commitment to developing innovative therapies for HDV and other rare diseases.
Eiger BioPharmaceuticals, based in Palo Alto, announced that CEO David Cory will deliver a corporate update at the H.C. Wainwright BioConnect 2022 Virtual Conference. This presentation will be pre-recorded and accessible on their website starting at 7:00 AM ET on January 10, 2022, for 90 days. Eiger is focused on developing therapies for Hepatitis Delta Virus (HDV) and other rare diseases, with five programs having received FDA Breakthrough Therapy Designation. The company aims to innovate treatments that directly target viral replication processes.
Eiger BioPharmaceuticals (Nasdaq:EIGR) has announced the enrollment of the first patient in its Phase 3 LIMT-2 study, examining Peginterferon Lambda for treating chronic Hepatitis Delta Virus (HDV). The study aims to enroll 150 patients across 50 sites in 13 countries, comparing a treatment group to a no-treatment group followed by treatment. The primary goal is to assess the Durable Virologic Response (DVR) at 24 weeks post-treatment. Eiger is pursuing regulatory approval, with Peginterferon Lambda already receiving Orphan Designation and Fast Track status from the FDA.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced that the Data Safety Monitoring Board (DSMB) has recommended the continuation of the Phase 3 TOGETHER study, following a second interim futility analysis involving 1,003 patients. The study aims to evaluate Peginterferon Lambda's effectiveness in high-risk COVID-19 patients, with a primary endpoint focused on emergency visits, hospitalizations, and deaths. The trial is set to enroll up to 1,600 patients across 12 sites in Brazil, highlighting the urgent need for new COVID-19 treatments.
FAQ
What is the market cap of Eiger BioPharmaceuticals (EIGR)?
What is Eiger BioPharmaceuticals' focus?
What are Eiger's lead products?
What recent strategic changes has Eiger made?
How is Eiger financially performing?
Who is leading Eiger BioPharmaceuticals?
What is the significance of the reverse stock split?
What is avexitide used for?
What is Zokinvy® (lonafarnib)?
What is the status of Eiger's virology assets?
Where can I find more information about Eiger?
